R&D News | pharmaphorum

News

Novartis gets win for another Avidity muscular dystrophy AOC

Novartis' $12bn takeover of Avidity could potentially give it the first therapy for genetic disorder facioscapulohumeral muscular dystrophy.

News

Anthropic puts life sciences at heart of new AI model

Anthropic has released Claude Fable 5, trumpeting its R&D credentials, but has faced a backlash over "safeguards" built into the model.

News

SonoThera's $125m Series B heads recent biofinancings

Our latest roundup of financings in the biotech sector includes impressive rounds for SonoThera, Ethyreal, CeQur, and City Therapeutics.

News

Cancer biotech Parabilis books record IPO, raising $670m

Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.

News

Stop sign with green fields in the background

Sanofi abandons phase 3 trial of neurology drug riliprubart

Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart in rare disease CIDP was stopped for futility.

News

Moderna Innovation and Technology Centre

Moderna jab on trial for cancer-causing syndrome

Patients with Lynch syndrome could have a potential treatment on the horizon, as a Moderna mRNA vaccine starts trials at Oxford University.

Novartis gets win for another Avidity muscular dystrophy AOC

Anthropic puts life sciences at heart of new AI model

SonoThera's $125m Series B heads recent biofinancings

Cancer biotech Parabilis books record IPO, raising $670m

Sanofi abandons phase 3 trial of neurology drug riliprubart

Moderna jab on trial for cancer-causing syndrome

FDA issues warning letters to five unapproved GLP-1 websites

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks